GlycoMimetics (NASDAQ:GLYC) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Wednesday.
Several other equities research analysts also recently issued reports on the company. Zacks Investment Research downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a report on Wednesday, February 20th. ValuEngine downgraded GlycoMimetics from a “buy” rating to a “hold” rating in a report on Monday, February 4th. HC Wainwright assumed coverage on GlycoMimetics in a report on Tuesday, December 18th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Roth Capital set a $35.00 price objective on GlycoMimetics and gave the stock a “buy” rating in a report on Monday, November 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. GlycoMimetics has a consensus rating of “Buy” and a consensus price target of $23.75.
Get GlycoMimetics alerts:GLYC stock opened at $12.29 on Wednesday. GlycoMimetics has a 52-week low of $8.29 and a 52-week high of $24.62. The company has a market cap of $505.57 million, a price-to-earnings ratio of -10.88 and a beta of 2.82.
Several hedge funds and other institutional investors have recently modified their holdings of GLYC. Prentiss Smith & Co. Inc. increased its holdings in shares of GlycoMimetics by 42.9% in the 4th quarter. Prentiss Smith & Co. Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 3,000 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in shares of GlycoMimetics by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,748 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 9,175 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of GlycoMimetics in the 4th quarter valued at approximately $114,000. Two Sigma Investments LP bought a new stake in shares of GlycoMimetics in the 4th quarter valued at approximately $152,000. Finally, WINTON GROUP Ltd bought a new stake in shares of GlycoMimetics in the 3rd quarter valued at approximately $186,000.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.
Featured Story: Diversification
No comments:
Post a Comment